Fig 1: Screening of hub proteins for imatinib resistance (A) Protein–protein interaction (PPI) networks of DEPs. (B–E) The top 20 proteins in cytoHubba plugins: Stress (B), Closeness (C), EcCentricity (D), and MCC (E). (F) Venn diagram of the top 20 genes by different algorithms. The numbers (16) in the red circles indicate the common hub proteins identified by four algorithms. (G) Comparison of the numbers of proteins in CML-R, CML-R3 and CML-S group. The numbers (62) in the red circles indicate 62 proteins that only exist in IM-R group (CML-AP, CML-BP, and CML-CP). (H) Venn diagrams of 16 hub proteins and 62 CML-R3 proteins. The four proteins (RPL13, RPL18A, RPS15A, and RPL13 were screened as candidate proteins. DEPs, differentially expressed proteins; CML-R, Proteins identified in the imatinib resistant group; CML-S, Proteins identified in the imatinib sensitive group; CML-R3, Proteins identified in the all imatinib resistant group.
Fig 2: Validation of plasma exosomal proteins RPL13 and RPL14 in independent cohorts. (A) The expression levels of RPL13 and RPL14 were detected by western blot in plasma exosome samples from 18 CML-R and 18 CML-S patients. TSG101 serves as an internal control for equivalent amounts of protein (15 µg). (B, C) The scatter diagram shown the quantified data of RPL14 (B) and RPL13 (C), respectively. CML-S, imatinib-sensitive chronic myeloid leukemia patients; CML-R, imatinib-resistant chronic myeloid leukemia patients. **p < 0.01, ***p < 0.001.
Supplier Page from Abcam for Anti-RPL13 antibody [EPR8828]